Pfiz­er's JAK1 chal­lenger to Dupix­ent shines in an­oth­er PhI­II, but safe­ty is­sues still cast a shad­ow

Pfiz­er is rack­ing up am­mu­ni­tion for its full-on as­sault against Re­gen­eron and Sanofi’s Dupix­ent fran­chise, with the lat­est topline win for an oral atopic der­mati­tis drug that it’s steer­ing to the FDA lat­er this year. But the new da­ta cut is do­ing lit­tle to ease safe­ty con­cerns.

JADE COM­PARE is the third Phase III tri­al in the abroc­i­tinib eczema pro­gram. Un­like JADE MONO-1 and JADE MONO-2, which en­rolled pa­tients who ei­ther don’t re­spond well or can’t tol­er­ate top­i­cal treat­ment, this new tri­al ze­roed in on those al­so tak­ing top­i­cal ther­a­pies on back­ground.

Michael Cor­bo

This ap­proach helps “pro­vide da­ta rel­e­vant to the re­al-world set­ting,” Michael Cor­bo, Pfiz­er’s chief de­vel­op­ment of­fi­cer for in­flam­ma­tion and im­munol­o­gy, not­ed in a state­ment.

In this set­ting, abroc­i­tinib met the co-pri­ma­ry end­points at week 12, which cap­ture two of the most com­mon mea­sures of eczema. The one on IGA de­notes the in­ves­ti­ga­tor’s as­sess­ment of clear (0) or al­most clear and a 2+ point re­duc­tion on a 5-point scale from base­line. The oth­er, EASI-75, counts the pro­por­tion of pa­tients who achieve at least 75% change from base­line in their Eczema Area and Sever­i­ty In­dex.

While Dupix­ent was in­clud­ed as the ac­tive con­trol, it wasn’t for­mal­ly com­pared to abroc­i­tinib ex­cept on a mi­nor end­point on rel­a­tive pru­ri­tus re­lief at week 2. There, Pfiz­er’s ex­per­i­men­tal drug in­duced a sta­tis­ti­cal­ly su­pe­ri­or re­duc­tion in itch. Its ex­ecs have pre­vi­ous­ly tout­ed faster re­lief as a po­ten­tial ad­van­tage over Dupix­ent.

From the lim­it­ed da­ta, Bri­an Sko­r­ney of Baird reck­ons abroc­i­tinib has com­pa­ra­ble ef­fi­ca­cy, but Dupix­ent like­ly has a slight edge on safe­ty.

Pfiz­er said the safe­ty pro­file seen here was con­sis­tent with pre­vi­ous stud­ies, which could be a prob­lem. Among five treat­ment arms com­pris­ing vary­ing dos­es of abroc­i­tinib, Dupix­ent and place­bo, ad­verse events were most com­mon among the group re­ceiv­ing 200mg (61.9%). By com­par­i­son, 50% of the Dupix­ent group, 50.8% of those tak­ing abroc­i­tinib 100mg, and 53.4% among the two groups tak­ing place­bo ex­pe­ri­enced a side ef­fect.

JAK in­hibitors as a class have run in­to se­ri­ous safe­ty is­sues that forced reg­u­la­tors to lim­it dos­ing — some­thing Pfiz­er’s tra­vails with Xel­janz have un­der­scored. It ap­pears that abroc­i­tinib, which tar­gets the JAK1 sub­type, is still plagued with sim­i­lar prob­lems, with pre­vi­ous­ly re­port­ed in­stances of nau­sea and headache, as well as po­ten­tial in­creased risk of throm­bo­cy­tope­nia and meta­bol­ic dis­or­ders.

Ab­b­Vie’s FDA ap­proval for its oral JAK1 drug Rin­voq (for rheuma­toid arthri­tis no less) came with a black box warn­ing.

By block­ing the Janus ki­nase, abroc­i­tinib is thought to mod­u­late mul­ti­ple cy­tokines in­clud­ing IL-4, IL-13, IL-31, IL-22 and in­ter­fer­on gam­ma. Dupix­ent, on the oth­er hand, in­hibits IL-4 and IL-13 di­rect­ly.

If physi­cians and pa­tients can look be­yond the safe­ty con­cerns — a big if — one fi­nal fac­tor might be­come cru­cial in Pfiz­er’s fight: the con­ve­nience of dos­ing.

“While the ju­ry is still out with re­spect to the com­pa­ra­bil­i­ty of the clin­i­cal pro­files of Dupix­ent and abroc­i­tinib, we must note that if abroc­i­tinib pro­vides a sim­i­lar pro­file to Dupix­ent, but in a pill form, it could serve as a ma­jor threat to Re­gen­eron’s key sub­cu­ta­neous prod­uct (Dupix­ent),” Sko­r­ney wrote.

Bob Nelsen at the Milken Institute Global Conference on April 29, 2019 in Beverly Hills, California. (Photo by Michael Kovac/Getty Images)

ARCH chief Bob Nelsen has $1.5B to prove 2 sim­ple points: ‘We’re in the most in­no­v­a­tive time ever’ and in­vestors are stay­ing

ARCH co-founder and managing director Bob Nelsen has a well known yen for the home run swing, betting big on potentially transformative meds and tech and the biotech teams he helps bring together. He thrives and bleeds on the cutting edge. And now Nelsen and the ARCH group have debuted 2 big funds to prove that this is the time for the best of biotech to shine — deadly pandemic be damned.

Two new funds, ARCH Venture Fund X and ARCH Venture Fund X Overage, gathered a combined $1.46 billion. And that’s a record. ARCH Venture Fund IX and ARCH Venture Fund IX Overage closed in 2016 with a combined $1.1 billion. ARCH Venture Fund VIII and ARCH Venture Fund VIII Overage closed in 2014 with a combined $560 million.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: No­var­tis, In­cyte pitch Jakafi PhI­II to tack­le se­vere cas­es; Is coro­n­avirus spread­ing like measles?

Novartis, which has so far taken a supporting role in the global R&D campaign against Covid-19, is stepping up to launch its own clinical trial. Together with Incyte, the Swiss pharma giant will test their partnered Jakafi in patients who experience cytokine storm as a result of the coronavirus infection.

Marketed as Jakavi outside of the US, the JAK1/2 inhibitor is a blockbuster product that’s already approved for a number of cancers and graft versus host disease. Incyte noted that many Covid-19 patients with severe respiratory disease appear to have “increased activation of the JAK-STAT pathway.” Novartis added that preclinical evidence and preliminary reports form independent studies support their decision to go ahead with a Phase III.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

J&J gives pi­o­neer­ing stem cell biotech its first Big Phar­ma deal, part­ner­ing on iP­SC CAR-T and CAR-NK

Late last summer, one of the earliest stem cell therapy companies got two government decisions in the span of three weeks: The USPTO granted them a patent for iPSC-derived CAR-T cells, and then the FDA cleared them for their first-in-human CAR-NK trial.

Yesterday, the two technologies landed them an up-to $3.1 billion deal.

Fate Therapeutics and J&J announced a global collaboration that will pay Fate $100 million upfront and a trove of potential milestones to develop multiple CAR-T and CAR-NK therapies. It’s the first Big Pharma partnership Fate has announced in their 13-year existence and the largest, although at least one longtime follower thought they could have landed more.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

Drug dis­cov­ery in the age of coro­n­avirus

Developing new drugs is incredibly hard. That’s why, despite superhuman efforts from the industry, we’re still looking at 12-18 months minimum before we can realistically hope for a vaccine for Covid-19, and probably months before there’s a proven viable drug treatment.

But our increasing ability to begin to industrialize the drug discovery and development process through an engineering approach means that we have more hope for speeding up this process than ever before — and not just to defeat coronavirus, but to benefit the development of all new medicines in the future.

UP­DAT­ED: Have a new drug that promis­es to fight Covid-19? The FDA promis­es fast ac­tion but some de­vel­op­ers aren't hap­py

After providing an emergency approval to use malaria drugs against coronavirus with little actual evidence of their efficacy or safety in that setting, the FDA has already proven that it has set aside the gold standard when it comes to the pandemic. And now regulators have spelled out a new approach to speeding development that promises immediate responses in no uncertain terms — promising a program offering the ultimate high-speed pathway to Covid-19 drug approvals.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

Once fu­ri­ous over No­var­tis’ da­ta ma­nip­u­la­tion scan­dal, the FDA now says it’s noth­ing they need to take ac­tion on

Back in the BP era — Before Pandemic — the FDA ripped Novartis for its decision to keep the agency in the dark about manipulated data used in its application for Zolgensma while its marketing application for the gene therapy was under review.

Civil and criminal sanctions were being discussed, the agency noted in a rare broadside at one of the world’s largest pharma companies. Notable lawmakers cheered the angry regulators on, urging the FDA to make an example of Novartis, which fielded Zolgensma at $2.1 million — the current record for a one-off therapy.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

Covid-19 roundup: GSK, Am­gen tai­lor R&D work to fit the coro­n­avirus age; Doud­na's ge­nomics crew launch­es di­ag­nos­tic lab

You can add Amgen and GSK to the list of deep-pocket drug R&D players who are tailoring their pipeline work to fit a new age of coronavirus.

Following in the footsteps of a lineup of big players like Eli Lilly — which has suspended patient recruitment for drug studies — Amgen and GSK have opted to take a more tailored approach. Amgen is intent on circling the wagons around key studies that are already fully enrolled, and GSK has the red light on new studies while the pandemic plays out.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

In a stun­ning set­back, Amarin los­es big patent fight over Vas­cepa IP. And its high-fly­ing stock crash­es to earth

Amarin’s shares $AMRN were blitzed Monday evening, losing billions in value as reports spread that the company had lost its high-profile effort to keep its Vascepa patents protected from generic drugmakers.

Amarin had been fighting to keep key patents under lock and key — and away from generic rivals — for another 10 years, but District Court Judge Miranda Du in Las Vegas ruled against the biotech. She ruled that:
(A)ll the Asserted Claims are invalid as obvious under 35 U.S.C.§ 103. Thus, the Court finds in favor of Defendants on Plaintiff’s remaining infringementclaim, and in their favor on their counterclaims asserting the invalidity of the AssertedClaims under 35 U.S.C. § 103.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.

Noubar Afeyan, Flagship

Step­ping out along­side ARCH's record raise, Flag­ship adds a $1.1B mon­ster fund of its own

ARCH’s unveiling this morning of 2 new funds bulging with $1.5 billion in cash for biotech startups was just the first round of today’s venture news.

Right on its heels we have another monster fund debuting at Flagship Pioneering, another big venture group known for making huge bets on cutting-edge tech — the kind it brews up in its labs.

And this one weighs in at $1.1 billion, which will operate in tandem with the $1.1 billion in funds Flagship rolled out last year.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 77,300+ biopharma pros reading Endpoints daily — and it's free.